Premium
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Author(s) -
Danial C.,
Lingala B.,
Balise R.,
Oro A.E.,
Reddy S.,
Colevas A.,
Chang A.L.S.
Publication year - 2013
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12333
Subject(s) - medicine , confidence interval , basal cell carcinoma , biopsy , proportional hazards model , retrospective cohort study , metastasis , overall survival , survival analysis , distant metastasis , oncology , surgery , basal cell , cancer
Summary Background Metastatic basal cell carcinoma ( BCC ) is a rare but life‐threatening condition. Prior estimates of overall survival ( OS ) from time of diagnosis of distant metastasis to death are approximately 8–14 months. However, these estimates are based on analyses of case reports published prior to 1984. Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution. Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy‐confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan–Meier analysis was used to determine OS and progression‐free survival ( PFS ). Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval ( CI ) 1·6–∞]; median PFS was 3·4 years (95% CI 1·1–5·2). Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.